Cargando…

Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

BACKGROUND: Immune-related enterocolitis (irEC) is the most common serious complication from checkpoint inhibitors (CPIs). The current front-line treatment for irEC, high-dose corticosteroids (CS), have significant side effects and prolonged therapy may reduce CPI-anti-tumor activity. Early addition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Daniel H, Zobniw, Chrystia M, Trinh, Van A, Ma, Junsheng, Bassett, Roland L, Abdel-Wahab, Noha, Anderson, Jaime, Davis, Jennifer E, Joseph, Jocelyn, Uemura, Marc, Noman, Ali, Abu-Sbeih, Hamzah, Yee, Cassian, Amaria, Rodabe, Patel, Sapna, Tawbi, Hussein, Glitza, Isabella C, Davies, Michael A, Wong, Michael K, Woodman, Scott, Hwu, Wen-Jen, Hwu, Patrick, Wang, Yinghong, Diab, Adi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180568/ https://www.ncbi.nlm.nih.gov/pubmed/30305177 http://dx.doi.org/10.1186/s40425-018-0412-0

Ejemplares similares

Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
por: Johnson, Daniel H., et al.
Publicado: (2019)

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
por: Glitza, Isabella C, et al.
Publicado: (2018)

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM)
por: Kim, Dae Won, et al.
Publicado: (2015)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma
por: Ogata, Dai, et al.
Publicado: (2021)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
por: Wang, Yinghong, et al.
Publicado: (2018)

Infliximab for the treatment of patients with checkpoint inhibitor–associated acute tubular interstitial nephritis
por: Lin, Jamie S., et al.
Publicado: (2021)

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials
por: Pelster, Meredith S., et al.
Publicado: (2019)

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023)

Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report
por: Gong, You-Zhe, et al.
Publicado: (2021)

Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature
por: Abdel-Wahab, Noha, et al.
Publicado: (2019)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021)

Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
por: Glitza Oliva, Isabella C., et al.
Publicado: (2023)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Update on use of aldesleukin for treatment of high-risk metastatic melanoma
por: Amaria, Rodabe N, et al.
Publicado: (2015)

RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma
por: Cooper, Zachary A., et al.
Publicado: (2016)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response
por: Parvathareddy, Vishnupriyadevi, et al.
Publicado: (2023)

GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
por: Patel, Sapna P., et al.
Publicado: (2016)

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes
por: Forget, Marie-Andrée, et al.
Publicado: (2017)

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma
por: Siroy, Alan E., et al.
Publicado: (2014)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2020)

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
por: Zhang, Hao Chi, et al.
Publicado: (2019)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
por: Kim, Teresa, et al.
Publicado: (2014)

Enterocolitis
por: Cobb, O. W.
Publicado: (1906)

Resolution of Infliximab-Refractory Nivolumab-Induced Acute Severe Enterocolitis After Cyclosporine Treatment in a Patient with Non-Small Cell Lung Cancer
por: Iyoda, Tomokazu, et al.
Publicado: (2018)

Paeniclostridium (Clostridium) sordellii–associated enterocolitis in 7 horses
por: Nyaoke, Akinyi C., et al.
Publicado: (2020)

Correction to: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ni5e75bgo7nphth4tlvqchcsot